News

Helping cells become better protein factories

New technique could improve gene therapies and other treatments
Daniel N. Hebert Lila Gierasch
By Daniel N. Hebert and Lila Gierasch
Aug. 21, 2022

The cells in your body are not all the same. Each of your organs has cells with very different functions. For example, liver cells are top-notch secretors, as their job requires them to make and export many of the proteins in your blood. By contrast, muscle cells are tasked with facilitating the contractions that allow you to move.

The fact that cells are so specialized has implications for gene therapy, a way to treat genetic diseases by correcting the source of the error in a patient’s DNA. Health providers use a harmless viral or bacterial vector to carry a corrective gene into a patient’s cells, where the gene then directs the cell to produce the proteins necessary to treat the disease. Muscle cells are a common target because gene therapies injected into the muscle are more accessible than introduction into the body by other routes. But muscle cells may not produce the desired protein as efficiently as needed if the job the gene instructs it to do is very different from the one it specializes in.

We are cell biologists and biophysicists who study how healthy proteins are produced and maintained in cells. This field is called protein homeostasis, also known as proteostasis. Our recently published study details a way to make muscle cells behave more like liver cells by changing protein regulation networks, enhancing their ability to respond to gene therapy and treat genetic diseases.

Gene therapy involves replacing a defective gene with a functioning one that can direct cells to produce missing or dysfunctional proteins.

Boosting protein factories

One disease for which gene therapy has great potential is alpha-1 antitrypsin (AAT) deficiency, a condition in which liver cells are unable to make adequate amounts of the protein AAT. It results in a breakdown of lung tissue that can cause serious respiratory problems, including the development of severe lung diseases such as chronic obstructive pulmonary disease (COPD) or emphysema.

Patients are usually treated by receiving AAT via infusion. But this requires patients to either make regular trips to the hospital or keep expensive equipment at home for the rest of their lives. Replacing the faulty gene that caused their AAT shortage in the first place could be a boon for patients. Current gene therapies inject the AAT-producing gene into muscle. One of our colleagues, Terence Flotte, developed a way to use a harmless version of an adeno-associated virus as a vehicle to deliver AAT gene therapies into the body via injection, allowing for sustained release of the protein over several years.

Lung damage from alpha-1 antitrypsin deficiency can lead to emphysema.
Lung damage from alpha-1 antitrypsin deficiency can lead to emphysema.

But muscle cells aren’t very good at producing the AAT proteins the gene instructs them to make. Flotte and his team found that AAT levels one to five years after gene therapy were only 2% to 2.5% of the optimal concentration for therapeutic effect.

We wanted to find a way to turn muscle cells into better protein factories, like liver cells. We tested a number of different molecules on mice muscle cells to determine if they would boost AAT secretion. We found that adding a molecule called suberoylanilide hydroxamic acid, or SAHA, helps muscle cells make AAT at a production level more like that of liver cells. It works because SAHA is a proteostasis regulator with the ability to boost the cell’s protein output.

Down the road, we believe that adding SAHA or similar proteostasis regulators to gene therapies could help increase the effectiveness of these treatments for many genetic diseases.

Beyond gene therapy

Our findings have implications beyond just gene therapies. The effectiveness of mRNA vaccines, for example, is also affected by how well each cell produces a particular type of protein. Because most mRNA vaccines are given through an injection to the muscle, they may also face the same limitations as gene therapies and produce a lower-than-desirable immune response. Increasing the protein production of muscle cells could potentially improve vaccine immunity.

Additionally, many drugs created by the biotech industry called biologics that are derived from natural sources rely heavily on a given cell’s protein production capabilities. But many of these drugs use cells that aren’t specialized to make large amounts of protein. Adding a protein homeostasis enhancer to the cell could optimize protein yield and increase the effectiveness of the drug.

Protein homeostasis is a burgeoning field that goes beyond drug development. Many neurodegenerative diseases like Alzheimer’s and Parkinson’s are linked to abnormal protein regulation. The deterioration of a cell’s ability to manage protein production and use over time may contribute to age-related diseases. Further research on ways to improve the cellular machinery behind protein homeostasis could help delay aging and open many new doors for treating a wide range of diseases.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

The Conversation

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Daniel N. Hebert
Daniel N. Hebert

Daniel N. Hebert is a professor of biochemistry and molecular biology at UMass Amherst.

Lila Gierasch
Lila Gierasch

Lila Gierasch is a distinguished professor of biochemistry and molecular biology at UMass Amherst.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Living in a bubble
Annual Meeting

Living in a bubble

Sept. 29, 2022

This symposium, Protein Machines and Disorder, will be part of #DiscoverBMB 2023.

Keep your friends close and your RNAs closer
Annual Meeting

Keep your friends close and your RNAs closer

Sept. 29, 2022

This symposium, Regulation of RNA, will be part of #DiscoverBMB 2023.

A membrane ATPase without transporter activity
Journal News

A membrane ATPase without transporter activity

Sept. 28, 2022

A classic article in the Journal of Biological Chemistry reflects on Guido Guidotti’s laboratory and the search for CD39.

The era of “smart” organelles
Annual Meeting

The era of “smart” organelles

Sept. 28, 2022

This symposium, Organelles, Mechanisms and Phase Properties of Cellular Quality Control, will be part of #DiscoverBMB 2023.

Lipids, lipids everywhere!
Annual Meeting

Lipids, lipids everywhere!

Sept. 27, 2022

This symposium, Lipid Dynamics and Signals in Membrane and Protein Structure, will be part of #DiscoverBMB 2023.

A target to prevent kidney injury by chemotherapy
Journal News

A target to prevent kidney injury by chemotherapy

Sept. 27, 2022

“Many people don’t realize that the side effects of chemotherapy are not limited to hair loss, diarrhea and nausea.”